The investment came from Korean investors such as Samho Green Investment and ST Capital, and strategic investors from the U.S. and China.
The investment is expected to accelerate FDA and CFDA approvals.
Medi Futures has commercialized ultrasonic endoscopic disk surgical instruments and enzyme-free ultrasound stem cell separators based on ultrasonic platform technology. Recently, the company has developed and exported medical sutures with high-precision anchoring points (barbed sutures).
Medi is a member company of the K-ICT Born2Global Centre and recently participated in a training program held at Medtronic’s Asia-Pacific Headquarters.
FinSMEs
30/12/2018